Abstract
Benefits and Limits of Risperidone-Methylphenidate Combination in Child Psychiatry: 3 Cases
Methylphenidate remains the first choice treatment for attention deficit hyperactivity disorder (ADHD), but comorbid forms with Disruptive Behaviour Disorders (DBD) are undertreated.
Methylphenidate adjunction is sometimes necessary in order to treat ADHD-related symptoms in DBD behaviors initially well-regulated with risperidone. In these situations, psychostimulant-antipsychotic combinations can be a useful strategy.
We report three cases of methylphenidate-risperidone combination in the context of our clinical experience with this bitherapy.
The cases show potential benefits to treat comorbid- ADHD with DBD with the psychostimulant-antipsychotic combination and the limits due to the risk of dyskinesia.
Author(s):
Hervé Javelot, Bruno Michel, Nicolas Didelot, Luisa Weiner, Claire Glay-Ribau, Bernard Kabuth
Abstract | Full-Text | PDF
Share this
Archives of Medicine peer review process verified at publons
Abstracted/Indexed in
- Google Scholar
- Genamics JournalSeek
- China National Knowledge Infrastructure (CNKI)
- Directory of Research Journal Indexing (DRJI)
- WorldCat
- Proquest Summons
- Publons
- Geneva Foundation for Medical Education and Research
- Secret Search Engine Labs
- Euro Pub
Open Access Journals
- Aquaculture & Veterinary Science
- Chemistry & Chemical Sciences
- Clinical Sciences
- Engineering
- General Science
- Genetics & Molecular Biology
- Health Care & Nursing
- Immunology & Microbiology
- Materials Science
- Mathematics & Physics
- Medical Sciences
- Neurology & Psychiatry
- Oncology & Cancer Science
- Pharmaceutical Sciences